

# Maria C. Haller

dob: September, 25<sup>th</sup> 1980 in Ried im Innkreis, Austria



## **Education**

### Degrees

March, 2012: Vienna University of Economics and Business Administration,  
Austria, Master of Business Administration (for Health Care Management)

June, 2006: Medical University of Vienna, Austria, medical doctor

March, 2016: Harvard School of Public Health, Boston, MA, USA, Master of Science in  
Epidemiology

### Training in Biostatistics and Epidemiology

Since October 2013: PhD program 'Medical Informatics, Biostatistics and Complex  
Systems', Medical University Vienna, Austria

October 2012 – April 2013: Training at Cochrane Center, Renal Group, Sydney, NSW,  
Australia

## **Clinical Positions**

### Residency for internal medicine/nephrology

April 2008 - present: Internal Medicine III, Department for Nephrology, Rheumatology,  
Hypertension and Transplantation, Krankenhaus der Elisabethinen, Linz, Austria

### Internship

October 2006 - March 2008: Krankenhaus der Barmherzigen Schwester, Ried im Innkreis,  
Austria

## **Research Positions**

June 2012 – present: ERBP-Fellow, Methods Support Team, European Renal Best  
Practice, European Renal Association

October 2012 – April 2013: Honorary Research Fellow, Cochrane Renal Group,  
Sydney, Australia

April 2010 – November 2010: Postdoctoral Fellow, Institute of Physiology, University  
of Zurich, Zurich, Switzerland

Referee for

Transplant International  
Nephrology, Dialysis, Transplantation  
European Journal of Clinical Investigation  
Transplant Library

**Awards and Fellowships**

2014: Dr. Walter Pilgerstorfer-Preis der Medizinischen Gesellschaft für Oberösterreich  
2014: Medical Scientific Fund of the Mayor of the City of Vienna  
2013: Habilitationsstipendiums des Landes Oberösterreich  
2012: European Renal Best Practice - Fellowship  
2008: Research Fellowship in Renal Physiology and Pathophysiology, Foundation for the  
Development of Internal Medicine in Europe.  
2006: Pulsion Young Researcher Award, Munich, Germany

**Publications**

Originals

- **Haller MC**, Royuela A, Nagler EV, Webster AC  
Steroid avoidance or withdrawal for kidney transplant recipients.  
*The Cochrane Library (in press)*
  
- Nagler EV, **Haller MC**, Van Biesen W, Vanholder R, Craig JC, Webster AC  
Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.  
*The Cochrane Library (under review)*
  
- **Haller MC**, Kainz A, Bear H, Oberbauer R  
Association of dialysis vintage on outcomes after kidney transplantation.  
*Kidney International (under review)*
  
- **Haller MC**, Nagler EV, Webster AC  
Health economic evaluations in nephrology: Quantity, Quality and Scope.  
*American Journal of Kidney Disease (under review)*

- van der Veer SN, **Haller MC**, Pittens C, Gallieni M, Inston N, Monros AM, van Biesen W  
Setting priorities for optimizing vascular access decision making - an international survey of patients and clinicians.  
*PLoS One. 2015 10(7):e0128228 Epub 2015 Jul 07.*
- **Haller MC**, van der Veer SN, Nagler EV, Tomson C, Lewington A, Hemmelgarn BR, Gallagher M, Rocco M, Obrador G, Vanholder R, Craig JC, Van Biesen W  
A survey on the methodological processes and policies of renal guideline groups as a first step to harmonize renal guidelines.  
*Nephrol Dial Transplant. 2015 Jul;30(7):1066-74*
- Krizanac D, Stratil P, Hoerburger D, Testori C, Wallmueller C, Schober A, Haugk M, **Haller MC**, Behringer W, Herkner H, Sterz , Holzer M  
Femoro-iliacal artery temperature monitoring is an excellent option during therapeutic hypothermia: an observational study.  
*Resuscitation 2013 Jun;84(6):805-9*
- **Haller MC**, Amatschek S, Wilflingseder J, Kainz A, Bielesz B, Pavik I, Serra A, Mohebbi M, Biber J, Wagner CA, Oberbauer R  
Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters.  
*PLoS One. 2012;7(7):e39229. Epub 2012 Jul 30.*
- **Haller MC**, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R  
Cost-effectiveness analysis of renal replacement therapy in Austria.  
*Nephrol Dial Transplant 2011 Sep;26(9):2988-95*
- Kainz A, Wilflingseder J, Mitterbauer C, **Haller MC**, Burghuber C, Perco P, Langer RM, Oberbauer R  
Steroid donor pretreatment to prevent postischemic renal allograft failure: a randomised, controlled trial.  
*Ann Interna Med. 2010 Aug 17;153(4):222-30*

- Schmittinger CA, Dünser MW, **Haller MC**, Ulmer H, Luckner G, Torgersen C, Jochberger S, Hasibeder WR  
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression.  
*Crit Care. 2008;12(4):R99.*

Guidelines, Position Statements

- Abramowicz A, Hazzan M, Maggiore U, Peruzzi L, Cochat P, Oberbauer R, **Haller MC** and Van Biesen W  
Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP.  
*Nephrol Dial Transplant. 2015 Nov 12. [Epub ahead of print]*
- Bilo H, Coentrão L, Couchoud C, Covic A, De Sutter J, Drechsler C, Gnudi L, Goldsmith D, Heaf J, Heimbürger O, Jager KJ, Nacak H, Soler MJ, Van Huffel L, Tomson C, Van Laecke S, Weekers L, Wieçek A, Bolignano D, **Haller MC**, Nagler E, Nistor I, van der Veer S, Van Biesen W  
Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)  
*Nephrol Dial Transplant. 2015 May;30 Suppl 2:ii1-142.*
- Goldsmith D, Covic A, Vervloet M, Cozzolino M, Nistor I, Cozzolino M, Vervloet M, Brandenburg V, Bover J, Covic A, Evenepoel P, Goldsmith D, Massy Z, Mazzaferro S, Urena-Torres P, Abramowicz D, Bolignano D, Cannata Andia G, Cochat P, Covic A, Delvecchio L, Drechsler C, Eckardt KU, Fouque D, Fox J, **Haller MC**, Heimbürger O, Jager KJ, Lindley E, Marti Monros AM, Nagler E, Oberbauer R, Spasovski G, Tattersall J, Van Biesen W, Vander Veer S, Vanholder R, Wanner C, Wheeler D, Whithers W, Wiecek A, Zoccali C  
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.  
*Nephrol Dial Transplant. 2015 May;30(5):698-700*

- Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, **Haller MC**, van der Veer S, Van Biesen W, Nagler E  
Clinical practice guideline on diagnosis and treatment of hyponatraemia.  
*Nephrol Dial Transplant. 2014 Apr;29 Suppl 2:i1-i39*  
*Eur J Endocrinol. 2014 Feb 25;170(3):G1-47.*  
*Intensive Care Med. 2014 Mar;40(3):320-31.*

### Narratives

- Nistor I, Bolignano D, **Haller MC**, Nagler E, van der Veer SN, Jager K, Covic A, Webster A, Van Biesen W  
Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice.  
*Nephrol Dial Transplant. 2015 Oct 23.*
- Nagler EV, Webster AC, Bolignano D, **Haller MC**, Nistor I, van der Veer SN, Fouque D, Van Biesen W  
European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines.  
*Nephrol Dial Transplant. 2014 Apr;29(4):731-8.*
- **Haller MC**, Vanholder R, Oberbauer R, Zoccali C, Van Biesen W  
Health Economics and ERBP - Is it time to bring health economics into evidence based guideline production in Europe?  
*Nephrol Dial Transplant. 2013 Sep 5.*
- Amatschek S, **Haller MC**, Oberbauer R  
Renal phosphate handling in human – what can we learn from hereditary hypophosphatemias?  
*Eur J Clin Invest. 2010 Jun;40(6):552-60*

- **Haller MC**, Oberbauer R  
Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation.  
*Transpl Int 2009 Jan;22(1):69-77.*

5.5.2016

